Sufferers of skin conditions like acne, psoriasis and dermatitis could soon have effective cannabinoid therapeutics thanks to Botanix (ASX:BOT) and their synthetic cannabinoid trials. 

Presenting at the International Cannabinoid Derived Pharmaceuticals (iCDP) Summit in Boston, the presentation titled Fact or Fiction, highlighted the effectiveness seen in their recently completed clinical trials to treat acne, and a lack of regulation around existing over-the-counter cannabinoid therapeutics, 

“The iCDP Summit was a great opportunity to highlight the solid clinical and scientific data Botanix has generated, examining the efficacy of synthetic cannabidiol for treating skin diseases,” said Botanix Chairman and President, Vince Ippolito. 

“Our recent mechanism of action studies, combined with our completed and ongoing clinical studies, provide us with unique insights into the anti-inflammatory, immune-modulating and antimicrobial properties of synthetic cannabidiol.”

Key elements behind synthetic cannabinoid’s ability to treat skin irritations are it’s suppression of itchiness, kill bacteria and ability to modulate immune response, whilst Botanix’s study of current over-the-counter products should significantly less cannabinoid concentrate when tested, than listed on their labels. 

Having successfully completed a Phase 2 study of their acne treatment product, Botanix anticipates completing recruitment for their Phase 2 dermatitis study before the end of 2019.

“Our rapid development approach has distinguished us from our peers, many of whom have been in development for 5 to 15 years and are only now starting human studies for the first time,” said Ippolito.